Highlight Therapeutics' Marisol Quintero talks to Proactive London's Katie Pilbeam about their intention to extend the benefit of immunotherapies for patients who are not benefiting right now.
Quintero explains the plans for clinical trials of its lead product candidate BO-112.
The company recently announced that they have entered a second Phase II trial collaboration with a subsidiary of Merck & Co. And there are currently three ongoing trials in total.